Nicotine and cannabinoids: Parallels, contrasts and interactions

Neuroscience and Biobehavioral Reviews

Volumn 30, Issue 8, 2006, Pages 1161-1181

  Viveros, Maria Paz ^a   Marco, Eva M ^a   File, Sandra E ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adolescence; Cannabinoids; Functional interactions; Nicotine; Opposite effects; Shared pharmacological effects; Therapeutic implications

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; ENDOCANNABINOID; MECAMYLAMINE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NICOTINE; NICOTINIC RECEPTOR; RIMONABANT;

ANHEDONIA; ANXIETY; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEPRESSION; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG USE; DRUG WITHDRAWAL; EMOTIONAL STRESS; FEAR; FOOD INTAKE; HUMAN; LOW DRUG DOSE; MOOD CHANGE; NERVOUSNESS; NEUROSIS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SMOKING; SMOKING CESSATION; STRESS; TOBACCO DEPENDENCE; TRANQUILIZING ACTIVITY; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ANIMALS; ANXIETY; BEHAVIOR, ADDICTIVE; CANNABINOIDS; DRUG INTERACTIONS; EATING; HUMANS; MENTAL DISORDERS; NICOTINE; SUBSTANCE-RELATED DISORDERS;

EID: 33845273554     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2006.08.002     Document Type: Review

References (289)

1. Aceto M.D., Scates S.M., Ji Z., and Bowman E.R. Nicotine's opioid and anti-opioid interactions: proposed role in smoking behavior. European Journal of Pharmacology 248 (1993) 333-335
2. Adriani W., and Laviola G. Windows of vulnerability to psychopathology and therapeutic strategy in the adolescent rodent model. Behavioural Pharmacology 15 (2004) 341-352
3. Ameri A. The effects of cannabinoids on the brain. Progress in Neurobiology 58 (1999) 315-348
4. Anand R., Conroy W.G., Schoepfer R., Whiting P., and Lindstrom J. Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. Journal of Biological Chemistry 266 (1991) 11192-11198
5. Anda R.F., Croft J.B., Felitti V.J., Nordenberg D., Giles W.H., Williamson D.F., and Giovino G.A. Adverse childhood experiences and smoking during adolescence and adulthood. Journal of the American Medical Association 282 (1999) 1652-1658
6. Arévalo C., De Miguel R., and Hernández-Tristán R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacology Biochemistry and Behaviour 70 (2001) 123-131
7. Arguello P.A., and Jentsch J.D. Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat. Psychopharmacology (Berlin) 177 (2004) 141-150
8. Arseneault L., Cannon M., Witton J., and Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry 184 (2004) 110-117
9. Arthur D., and Levin E.D. Chronic inhibition of alpha4beta2 nicotinic receptors in the ventral hippocampus of rats: impacts on memory and nicotine response. Psychopharmacology 160 (2002) 140-145
10. Ashton C.H. Pharmacology and effects of cannabis: a brief review. British Journal of Psychiatry 178 (2001) 101-106
11. Australian Institute of Health and Wefare. Statistics on Drug Use in Australia 2004 (2005), Australian Institute of Health and Welfare, Camberra
12. Balerio G.N., Aso E., Berrendero F., Murtra P., and Maldonado R. Delta 9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. European Journal of Neuroscience 20 (2004) 2737-2748
13. Balerio G.N., Aso E., and Maldonado R. Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology 181 (2005) 260-269
14. Balerio G.N., Aso E., and Maldonado R. Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology 184 (2006) 504-513
15. Balfour D.J., and Ridley D.L. The effects of nicotine on neural pathways implicated in depression: a factor in nicotine addiction?. Pharmacology Biochemistry and Behaviour 66 (2000) 79-85
16. Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Experimental Neurology 163 (2000) 495-529
17. Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., Mo F.M., Liu J., and Kunos G. Evidence for novel cannabinoid receptors. Pharmacology and Therapeutics 106 (2005) 133-145
18. Bekker E.M., Bocker K.B., Van Hunsel F., van den Berg M.C., and Kenemans J.L. Acute effects of nicotine on attention and response inhibition. Pharmacology Biochemistry and Behaviour 82 (2005) 539-548
19. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., and Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 (1997) 1094-1097
20. Benowitz N.L. Nicotine addiction. Primary Care 26 (1999) 611-631
21. Berrendero F., and Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by delta (9)-tetrahydrocannabinol. Psychopharmacology 163 (2002) 111-117
22. Berrendero F., Mendizabal V., Robledo P., Galeote L., Bilkei-Gorzo A., Zimmer A., and Maldonado R. Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. Journal of Neuroscience 25 (2005) 1103-1112
23. Breivogel C.S., Griffin G., Di Marzo V., and Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology 60 (2001) 155-163
24. Breslau N., Peterson E.L., Schultz L.R., Chilcoat H.D., and Andreski P. Major depression and stages of smoking. A longitudinal investigation. Archives of General Psychiatry 55 (1998) 161-166
25. Bruijnzeel A.W., and Gold M.S. The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. Brain Research Review 49 (2005) 505-528
26. Buisson B., and Bertrand D. Chronic exposure to nicotine upregulates the human alpha4beta2 nicotinic acetylcholine receptor function. Journal of Neurosciences 21 (2001) 1819-1829
27. Buisson B., and Bertrand D. Nicotine addiction: the possible role of functional upregulation. Trends in Pharmacological Sciences 23 (2002) 130-136
28. Caan B., Coates A., Schaefer C., Finkler L., Sternfeld B., and Corbett K. Women gain weight 1 year after smoking cessation while dietary intake temporarily increases. Journal of the American Dietetic Association 96 (1996) 1150-1155
29. Campbell K.A., Foster T.C., Hampson R.E., and Deadwyler S.A. Delta 9-tetrahydrocannabinol differentially affects sensory-evoked potentials in the rat dentate gyrus. Journal of Pharmacology and Experimental Therapeutics 239 (1986) 936-940
30. Campbell K.A., Foster T.C., Hampson R.E., and Deadwyler S.A. Effects of delta 9-tetrahydrocannabinol on sensory-evoked discharges of granule cells in the dentate gyrus of behaving rats. Journal of Pharmacology and Experimental Therapeutics 239 (1986) 941-945
31. Castañé A., Berrendero F., and Maldonado R. The role of the cannabinoid system in nicotine addiction. Pharmacology Biochemistry and Behaviour 81 (2005) 381-386
32. Castañé A., Valjent E., Ledent C., Parmentier M., Maldonado R., and Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 43 (2002) 857-867
33. Cheeta S., Kenny P.J., and File S.E. The role of 5-HT1A receptors in mediating the anxiogenic effects of nicotine following lateral septal administration. European Journal of Neuroscience 12 (2000) 3797-3802
34. Cheeta S., Irvine E.E., and File S.E. Social isolation modifies nicotine's effects in animal tests of anxiety. British Journal of Pharmacology 132 (2001) 1389-1395
35. Cheeta S., Irvine E.E., Kenny P.J., and File S.E. The dorsal raphe nucleus is a crucial structure mediating nicotine's anxiolytic effects and the development of tolerance and withdrawal responses. Psychopharmacology 155 (2001) 78-85
36. Cheeta S., Irvine E.E., Tucci S., Sandhu J., and File S.E. In adolescence, female rats are more sensitive to the anxiolytic effect of nicotine than are male rats. Neuropsychopharmacology 25 (2001) 601-607
37. Cheeta S., Tucci S., and File S.E. Antagonism of the anxiolytic effect of nicotine in the dorsal raphe nucleus by dihydro-beta-erythroidine. Pharmacology Biochemistry and Behaviour 70 (2001) 491-496
38. Chen J., and Millar W.J. Age of smoking initiation: implications for quitting. Health Reports 9 (1998) 39-46
39. Cheng S.Y., Glazkova D., Serova L., and Sabban E.L. Effect of prolonged nicotine infusion on response of rat catecholamine biosynthetic enzymes to restraint and cold stress. Pharmacology Biochemistry and Behaviour 82 (2005) 559-568
40. Chhatwal J.P., Davis M., Maguschak K.A., and Ressler K.J. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 30 (2005) 516-524
41. Clough A.R. Associations between tobacco and cannabis use in remote indigenous populations in Northern Australia. Addiction 100 (2005) 346-353
42. Cohen S., and Lichtenstein E. Perceived stress, quitting smoking, and smoking relapse. Health Psychology 9 (1990) 466-478
43. 1 receptor antagonists for the treatment of nicotine addiction. Pharmacology Biochemistry and Behaviour 81 (2005) 387-395
44. Cohen C., Perrault G., Griebel G., and Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 30 (2005) 145-155
45. 1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behavioural Brain Research 118 (2001) 61-65
46. Cota D., Marsicano G., Tschop M., Grubler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thone-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A.C., Pasquali R., Lutz B., Stalla G.K., and Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation 112 (2003) 423-431
47. Covey L.S., Glassman A.H., and Stetner F. Cigarette smoking and major depression. Journal of Addictive Diseases 17 (1998) 35-46
48. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., and Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996) 83-87
49. Crisp A., Sedgwick P., Halek C., Joughin N., and Humphrey H. Why may teenage girls persist in smoking?. Journal of Adolescence 22 (1999) 657-672
50. Cryan J.F., Gasparini F., van Heeke G., and Markou A. Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. Drug Discovery Today 8 (2003) 1025-1034
51. Dannon P.N., Lowengrub K., Amiaz R., Grunhaus L., and Kotler M. Comorbid cannabis use and panic disorder: short term and long term follow-up study. Human Psychopharmacology 19 (2004) 97-101
52. Després J.P., Golay A., and Sjostrom L. Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine 353 (2005) 2121-2134
53. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
54. Di Marzo V., and Matias I. Endocannabinoid control of food intake and energy balance. Nature Neuroscience 8 (2005) 585-589
55. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., and Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372 (1994) 686-691
56. Di Marzo V., Breivogel C.S., Tao Q., Bridgen D.T., Razdan R.K., Zimmer A.M., Zimmer A., and Martin B.R. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. Journal of Neurochemistry 75 (2000) 2434-2444
57. Dineley-Miller K., and Patrick J. Gene transcripts for the nicotinic acetylcholine receptor subunit, beta4, are distributed in multiple areas of the rat central nervous system. Molecular Brain Research 16 (1992) 339-344
58. Eck L.H., Klesges R.C., Meyers A.W., Slawson D.L., and Winders S.A. Changes in food consumption and body weight associated with smoking cessation across menstrual cycle phase. Addictive Behaviour 22 (1997) 775-782
59. Edelstein S.J., Schaad O., Henry E., Bertrand D., and Changeux J.P. A kinetic mechanism for nicotinic acetylcholine receptors based on multiple allosteric transitions. Biological Cybernetics 75 (1996) 361-379
60. Egerton A., Brett R.R., and Pratt J.A. Acute delta (9)-tetrahydrocannabinol-induced deficits in reversal learning: neural correlates of affectiveinflexibility. Neuropsychopharmacology 30 (2005) 1895-1905
61. Egerton A., Allison C., Brett R.R., and Pratt J.A. Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neuroscience and Biobehavioural Reviews 30 (2006) 680-695
62. Eichenbaum H. Hippocampus cognitive processes and neural representations that underlie declarative memory. Neuron 44 (2004) 109-120
63. Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J., Hebert L.E., Hennekens C.H., and Taylor J.O. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. Journal of the American Medical Association 262 (1989) 2551-2556
64. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. Journal of Pharmacology and Experimental Therapeutics 313 (2005) 352-358
65. Field M., and Duka T. Smoking expectancy mediates the conditioned responses to arbitrary smoking cues. Behavioural Pharmacology 12 (2001) 183-194
66. File S.E. Interactions of anxiolytic and antidepressant drugs with hormones of the hypothalamic-pituitary-adrenal axis. In: File S.E. (Ed). Psychopharmacology of Anxiolytics and Antidepressants (1991), Pergamon Press, New York 29-56
67. File S.E., Cheeta S., and Kenny P.J. Neurobiological mechanisms by which nicotine mediates different types of anxiety. European Journal of Pharmacology 393 (2000) 231-236
68. File S.E., Fluck E., and Leahy A. Nicotine has calming effects on stress-induced mood changes in females, but enhances aggressive mood in males. International Journal of Neuropsychopharmacology 4 (2001) 371-376
69. File S.E., Kenny P.J., and Ouagazzal A.M. Bimodal modulation by nicotine of anxiety in the social interaction test: role of the dorsal hippocampus. Behavioural Neuroscience 112 (1998) 1423-1429
70. File S.E., Cheeta S., Irvine E.E., Tucci S., and Akthar M. Conditioned anxiety to nicotine. Psychopharmacology 164 (2002) 309-317
71. File S.E., Dinnis A.K., Heard J.E., and Irvine E.E. Mood differences between male and female light smokers and nonsmokers. Pharmacology Biochemistry and Behaviour 72 (2002) 681-689
72. Filozof C., Fernandez-Pinilla M.C., and Fernandez-Cruz A. Smoking cessation and weight gain. Obesity Review 5 (2004) 95-103
73. Flaherty C.F. Incentive contrast and selected animal models of anxiety. In: Dachowski L., and Flaherty C.F. (Eds). Current Topics in Animal Learning: Brain, Emotion, and Cognition (1991), Erlbaum, Hillsdale, NJ 207-243
74. Flaherty C.F., Becker H.C., and Driscoll C. Conditions under which amobarbital sodium influences contrast in consummatory behavior. Physiological Psychology 10 (1982) 122-128
75. Flaherty C.F., Becker H.C., and Pohorecky LA. Correlation of corticosterone elevation and negative contrast varies as a function of post-shift day. Animal Learning and Behaviour 13 (1985) 309-314
76. Flaherty C.F., Grigson P.S., and Lind S. Chlordiazepoxide and the moderation of the initial response to reward reduction. Quarterly Journal of Experimental Psychology B 42 (1990) 87-105
77. Flaherty C.F., Greenwood A., Martin J., and Leszczuk M. Relationship of negative contrast to animal models of fear and anxiety. Animal Learning and Behaviour 26 (1998) 397-407
78. 1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology 181 (2005) 722-734
79. Foulds J., Stapleton J., Swettenham J., Bell N., McSorley K., and Russell M.A. Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers. Psychopharmacology 127 (1996) 31-38
80. Fride E. Endocannabinoids in the central nervous system: from neuronal networks to behavior. Current Drug Targets-CNS Neurological Disorders 4 (2005) 633-642
81. Fride E., Ginzburg Y., Breuer A., Bisogno T., Di Marzo V., and Mechoulam R. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. European Journal of Pharmacology 419 (2001) 207-214
82. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G., and Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry 232 (1995) 54-61
83. Gardner E.L. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacology Biochemistry and Behaviour 81 (2005) 263-284
84. Genn R.F., Tucci S., Edwards J.E., and File S.E. Dietary restriction and nicotine can reduce anxiety in female rats. Neuropsychopharmcology 28 (2003) 1257-1263
85. Genn R.F., Tucci S., Marco E., Viveros M.P., and File S.E. Anxiolytic and anxiogenic effects of the cannabinoid agonist CP 55,940 in animal tests of anxiety. Journal of Psychopharmacology 17 (2003) A27
86. Genn R.F., Tucci S.A., Thomas A., Edwards J.E., and File S.E. Age-associated sex differences in response to food deprivation in two animal tests of anxiety. Neuroscience and Biobehavioural Reviews 27 (2003) 155-161
87. Genn R.F., Tucci S., Marco E.M., Viveros M.P., and File S.E. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacology Biochemistry and Behaviour 77 (2004) 567-573
88. Genn R.F., Tucci S., Parikh S., and File S.E. Effects of nicotine and a cannabinoid receptor agonist on negative contrast: distinction between anxiety and disappointment?. Psychopharmacology 177 (2004) 93-99
89. Ghozland S., Matthes H.W.D., Simonin F., Filliol D., Kieffer B.L., and Maldonado R. Motivational effects of cannabinoids are mediated by μ-opioid and κ-opioid receptors. Journal of Neuroscience 22 (2002) 1146-1154
90. Gifford A.N., Bruneus M., Lin S., Goutopoulos A., Makriyannis A., Volkow N.D., and Gatley S.J. Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374). European Journal of Pharmacology 383 (1999) 9-14
91. Gilbert D.G., and Gilbert B.O. Personality, psychopathology, and nicotine response as mediators of the genetics of smoking. Behaviour Genetics 25 (1995) 133-147
92. González S., Cascio M.G., Fernandez-Ruiz J.J., Fezza F., Di Marzo V., and Ramos J.A. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Research 954 (2002) 73-81
93. Gould T.J., and Wehner J.M. Nicotine enhancement of contextual fear conditioning. Behavioural Brain Research 102 (1999) 31-39
94. Green M.S., and Harari G. A prospective study of the effects of changes in smoking habits on blood count, serum lipids and lipoproteins, body weight and blood pressure in occupationally active men. The Israeli CORDIS Study. Journal of Clinical Epidemiology 48 (1995) 1159-1166
95. Hájos N., Ledent C., and Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106 (2001) 1-4
96. Hall W., and Solowij N. Adverse effects of cannabis. Lancet 352 (1998) 1611-1616
97. Hall, W., Solowij, N., Lemon, J., 1994. The Health and Psychological Consequences of Cannabis Use. National Drug Strategy Monograph, Series No. 25. Australian Government Publishing Service, Canberra.
98. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., and Mechoulam R. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Science 98 (2001) 3662-3665
99. Hatsukami D., LaBounty L., Hughes J., and Laine D. Effects of tobacco abstinence on food intake among cigarette smokers. Health Psychology 12 (1993) 499-502
100. Health and Welfare Canada. National Population Health Survey Highlights: Smoking Behaviour of Canadians-Cycle 2, 1996/97 (1999), Ontario Ministry of Health, Ottawa
101. Heishman S.J., Taylor R.C., and Henningfield J.E. Nicotine and smoking: A review of effects on human performance. Experimental and Clinical Psychopharmacology 2 (1994) 345-395
102. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Cannabinoid receptor localization in brain. Proceedings of the National Academy of Science, USA 87 (1990) 1932-1936
103. Hernandez L., and Hoebel B.G. Feeding and hypothalamic stimulation increase dopamine turnover in the accumbens. Physiological Behaviour 44 (1988) 599-606
104. Hernandez L., and Hoebel B.G. Food reward and cocaine increase extracellular dopamine in the nucleus accumbens as measured by microdialysis. Life Sciences 42 (1988) 1705-1712
105. Heyser C.J., Hampson R.E., and Deadwyler S.A. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task-specific firing of hippocampal cells. Journal of Pharmacy and Experimental Therapeutics 264 (1993) 294-307
106. Highet G. The role of cannabis in supporting young people's cigarette smoking: a qualitative exploration. Health Education Research 19 (2004) 635-643
107. Hillard C.J., Edgemond W.S., Jarrahian A., and Campbell W.B. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. Journal of Neurochemistry 69 (1997) 631-638
108. Hodgkins C.C., Cahill K.S., Seraphine A.E., Frost-Pineda K., and Gold M.S. Adolescent drug addiction treatment and weight gain. Journal of Addictive Disease 23 (2004) 55-65
109. Hoebel B.G., Hernandez L., Schwartz D.H., Mark G.P., and Hunter G.A. Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. Theoretical and clinical implications. Annals of the New York Academy of Science 575 (1989) 171-191
110. Hogg R.C., and Bertrand D. Nicotinic acetylcholine receptors as drug targets. Current Drug Targets in CNS Neurological Disorders 3 (2004) 123-130
111. Hollister L.E. Health aspects of cannabis. Pharmacological Review 38 (1986) 1-20
112. 9 THC and anandamide. Brain Research 857 (2000) 337-342
113. Howlett A.C. The CB1 cannabinoid receptor in the brain. Neurobiological Disease 5 (1998) 405-416
114. Hu S., Brody C.L., Fisher C., Gunzerath L., Nelson M.L., Sabol S.Z., Sirota L.A., Marcus S.E., Greenberg B.D., Murphy D.L., and Hamer D.H. Interaction between the serotonin transporter gene and neuroticism in cigarette smoking behavior. Molecular Psychiatry 5 (2000) 181-188
115. Huang S.M., Bisogno T., Trevisani M., Al-Hayani A., De Petrocellis L., Fezza F., Tognetto M., Petros T.J., Krey J.F., Chu C.J., Miller J.D., Davies S.N., Geppetti P., Walker J.M., and Di Marzo V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proceedings of the National Academy of Science, USA 99 (2002) 8400-8405
116. Hughes J.R., and Hatsukami D. Signs and symptoms of tobacco withdrawal. Archives of General Psychiatry 43 (1986) 289-294
117. Hughes J.R., Hatsukami D.K., Pickens R.W., Krahn D., Malin S., and Luknic A. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology 83 (1984) 82-87
118. Hughes J.R., Gust S.W., Keenan R.M., and Fenwick J.W. Effect of dose on nicotine's reinforcing, withdrawal-suppression and self-reported effects. Journal of Pharmacology and Experimental Therapeutics 252 (1990) 1175-1183
119. Humfleet G.L., and Haas A.L. Is marijuana use becoming a 'gateway' to nicotine dependence?. Addiction 99 (2004) 5-6
120. Irvine E.E., Cheeta S., and File S.E. Time-course of changes in the social interaction test of anxiety following acute and chronic administration of nicotine. Behavioural Pharmacology 10 (1999) 691-697
121. Irvine E.E., Bagnalasta M., Marcon C., Motta C., Tessari M., File S.E., and Chiamulera C. Nicotine self-administration and withdrawal: modulation of anxiety in the social interaction test in rats. Psychopharmacology 153 (2001) 315-320
122. Irvine E.E., Cheeta S., and File S.E. Development of tolerance to nicotine's anxiogenic effect in the social interaction test. Brain Research 894 (2001) 95-100
123. Irvine E.E., Cheeta S., and File S.E. Tolerance to nicotine's effects in the elevated plus-maze and increased anxiety during withdrawal. Pharmacology Biochemistry and Behaviour 68 (2001) 319-325
124. Irvine E.E., Cheeta S., Lovelock C., and File S.E. Tolerance to midazolam's anxiolytic effects after short-term nicotine treatment. Neuropharmacology 40 (2001) 710-716
125. Irvine E.E., Cheeta S., Marshall M., and File S.E. Different treatment regimens and the development of tolerance to nicotine's anxiogenic effects. Pharmacology Biochemistry and Behaviour 68 (2001) 769-776
126. Ismail Z., and el-Guebaly N. Nicotine and endogenous opioids: toward specific pharmacotherapy. Canadian Journal of Psychiatry 43 (1998) 37-42
127. Izenwasser, S., Wade, D., Collins, S.L., 2004. Chronic nicotine alters cannabinoid receptor density in adolescent male but not female or adult rats. In: Abstract from 14th Annual Symposium on the Cannabinoids, Paestum, Italy.
128. Jacobsen L.K., Krystal J.H., Mencl W.E., Westerveld M., Frost S.J., and Pugh K.R. Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biological Psychiatry 57 (2005) 56-66
129. Jacobsen, L.K., Pugh, K.R., Constable, R.T., Westerveld, M., Mencl, W.E., 2006. Functional correlates of verbal memory deficits emerging during nicotine withdrawal in abstinent adolescent cannabis users. Biol. Psychiatry, in press.
130. Jain K.K. Modulators of nicotinic acetylcholine receptors as analgesics. Current Opinion in Investigational Drugs 5 (2004) 76-81
131. Jarai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., Zimmer A.M., Bonner T.I., Buckley N.E., Mezey E., Razdan R.K., Zimmer A., and Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proceedings of the National Academy of Science, USA 96 (1999) 14136-14141
132. Jbilo O., Ravinet-Trillou C., Arnone M., Buisson I., Bribes E., Peleraux A., Penarier G., Soubrie P., Le Fur G., Galiegue S., and Casellas P. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB Journal 19 (2005) 1567-1569
133. Jo Y.H., Talmage D.A., and Role L.W. Nicotinic receptor-mediated effects on appetite and food intake. Journal of Neurobiology 53 (2002) 618-632
134. Jonsson K.O., Holt S., and Fowler C.J. The endocannabinoid system: current pharmacological research and therapeutic possibilities. Basic and Clinical Pharmacology and Toxicology 98 (2006) 124-134
135. Kanayama G., Rogowska J., Pope H.G., Gruber S.A., and Yurgelun-Todd D.A. Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology 176 (2004) 239-247
136. Kandel D.B., Yamaguchi K., and Chen K. Stages in the progression of drug involvement from adolescence to adulthood: further evidence for the Gateway Theory. Journal of Studies on Alcohol 53 (1992) 447-457
137. Kane J.K., Parker S.L., Matta S.G., Fu Y., Sharp B.M., and Li M.D. Nicotine up-regulates expression of orexin and its receptors in rat brain. Endocrinology 141 (2000) 3623-3629
138. Katner S.N., Davis S.A., Kirsten A.J., and Taffe M.A. Effects of nicotine and mecamylamine on cognition in rhesus monkeys. Psychopharmacology 175 (2004) 225-240
139. Kenny P.J., Cheeta S., and File S.E. Anxiogenic effects of nicotine in the dorsal hippocampus are mediated by 5-HT1A and not by muscarinic M1 receptors. Neuropharmacology 39 (2000) 300-307
140. Kenny P.J., File S.E., and Neal M.J. Evidence for a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release. Journal of Neurochemistry 75 (2000) 2409-2414
141. Kenny P.J., File S.E., and Rattray M. Nicotine regulates 5-HT(1A) receptor gene expression in the cerebral cortex and dorsal hippocampus. European Journal of Neuroscience 13 (2001) 1267-1271
142. Kirkham T.C. Cannabinoids and medicine: eating disorders, nausea and emesis. In: Di Marzo V. (Ed). Cannabinoids (2004), Kluwer Academic/Plenum Publishers, New York 147-160
143. Kirkham T.C. Endocannabinoids in the regulation of appetite and body weight. Behavioural Pharmacology 16 (2005) 297-313
144. Klink R., de Kerchove d'Exaerde A., Zoli M., and Changeux J.P. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. Journal of Neuroscience 21 (2001) 1452-1463
145. Kreitzer A.C., and Regehr W.G. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29 (2001) 717-727
146. Kreitzer A.C., and Regehr W.G. Retrograde signaling by endocannabinoids. Curr. Opin. Neurobiol. 12 (2002) 324-330
147. Lai S., Lai H., Page J.B., and McCoy C.B. The association between cigarette smoking and drug abuse in the United States. Journal of Addictive Diseases 9 (2000) 11-24
148. Laviola G., Adriani W., Terranova M.L., and Gerra G. Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models. Neuroscience and Biobehavioural Reviews 23 (1999) 993-1010
149. Le Foll B., Wiggins M., and Goldberg S.R. Nicotine pre-exposure does not potentiate the locomotor or rewarding effects of Δ-9-tetrahydrocannabinol in rats. Behavioural Pharmacology 17 (2006) 195-199
150. Le Novère N., Corringer P.J., and Changeux J.P. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. Journal of Neurobiology 53 (2002) 447-456
151. Leibowitz S.F., and Rossakis C. Analysis of feeding suppression produced by perifornical hypothalamic injection of catecholamines, amphetamines and mazindol. European Journal of Pharmacology 53 (1978) 69-81
152. Lerman C., Caporaso N.E., Audrain J., Main D., Boyd N.R., and Shields P.G. Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence. Molecular Psychiatry 5 (2000) 189-192
153. Lerman C., Berrettini W., Pinto A., Patterson F., Crystal-Mansour S., Wileyto E.P., Restine S.L., Leonard D.G., Shields P.G., and Epstein L.H. Changes in food reward following smoking cessation: a pharmacogenetic investigation. Psychopharmacology 174 (2004) 571-577
154. Levin E.D., and Rezvani A.H. Development of nicotinic drug therapy for cognitive disorders. European Journal of Pharmacology 393 (2000) 141-146
155. Levin E.D., Conners C.K., Sparrow E., Hinton S.C., Erhardt D., Meck W.H., Rose J.E., and March J. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 123 (1996) 55-63
156. Levin E.D., Kim P., and Meray R. Chronic nicotine working and reference memory effects in the 16-arm radial maze: interactions with D1 agonist and antagonist drugs. Psychopharmacology 127 (1996) 25-30
157. Levin E.D., Kaplan S., and Boardman A. Acute nicotine interactions with nicotinic and muscarinic antagonists: working and reference memory effects in the 16-arm radial maze. Behavioural Pharmacology 8 (1997) 236-242
158. Levin E.D., Bradley A., Addy N., and Sigurani N. Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience 109 (2002) 757-765
159. Levin E.D., McClernon F.J., and Rezvani A.H. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology 184 (2006) 523-539
160. Li M.D., and Kane J.K. Effect of nicotine on the expression of leptin and forebrain leptin receptors in the rat. Brain Research 991 (2003) 222-231
161. Li M.D., Kane J.K., Parker S.L., McAllen K., Matta S.G., and Sharp B.M. Nicotine administration enhances NPY expression in the rat hypothalamus. Brain Research 867 (2000) 157-164
162. Li M.D., Parker S.L., and Kane J.K. Regulation of feeding-associated peptides and receptors by nicotine. Molecular Neurobiology 22 (2000) 143-165
163. Lichtman A.H., Varvel S.A., and Martin B.R. Endocannabinoids in cognition and dependence. Prostaglandins Leukotrienes and Essential Fatty Acids 66 (2002) 269-285
164. Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacology Biochemistry and Behaviour 81 (2005) 319-330
165. Lynskey M.T., Heath A.C., Bucholz K.K., Slutske W.S., Madden P.A.F., Nelson E.C., Statham D.J., and Martin N.G. Escalation of drug use in early-onset cannabis users vs. co-twin controls. Journal of the American Medical Association 289 (2003) 427-433
166. Lyon E.R. A review of the effects of nicotine on schizophrenia and antipsychotic medications. Psychiatric Services 50 (1999) 1346-1350
167. Macritchie K.A., and Young A.H. Emerging targets for the treatment of depressive disorder. Expert Opinion on Therapeutic Targets 5 (2001) 601-612
168. Mailleux P., and Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48 (1992) 655-668
169. Mancuso G., Andres P., Ansseau M., and Tirelli E. Effects of nicotine administered via a transdermal delivery system on vigilance: a repeated measure study. Psychopharmacology 142 (1999) 18-23
170. Manzanares J., Corchero J., and Fuentes J.A. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of Δ9-tetrahydrocannabinol in rats. Brain Research 839 (1999) 173-179
171. Manzanares J., Corchero J., Romero J., Fernández-Ruiz J.J., Ramos J.A., and Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends in Pharmacological Science 20 (1999) 287-294
172. Marco E.M., Pérez-Álvarez L., Borcel E., Rubio M., Guaza C., Ambrosio E., File S.E., and Viveros M.P. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behavioural Pharmacology 15 (2004) 21-27
173. Marco E.M., Llorente R., Pérez-Álvarez L., Moreno E., Guaza C., and Viveros M.P. The κ-opioid receptor is involved in the stimulating effect of nicotine on adrenocortical activity but not in nicotine induced anxiety. Behavioural Brain Research 163 (2005) 212-218
174. Marco E.M., Llorente R., Moreno E., Biscaia J.M., Guaza C., and Viveros M.P. Adolescent exposure to nicotine modifies acute functional responses to cannabinoid agonists in rats. Behavioural Brain Research 172 (2006) 46-53
175. Marín S., Marco E., Biscaia M., Fernandez B., Rubio M., Guaza C., Schmidhammer H., and Viveros M.P. Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacology Biochemistry and Behaviour 74 (2003) 649-656
176. Markou A., Kosten T.R., and Koob G.F. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18 (1998) 135-174
177. Marks M.J., Pauly J.R., Gross S.D., Deneris E.S., Hermans-Borgmeyer I., Heinemann S.F., and Collins A.C. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. Journal of Neuroscience 12 (1992) 2765-2784
178. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgansberger W., Di Marzo V., and Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418 (2002) 530-534
179. Martin C.A., Logan T.K., Portis C., Leukefeld C.G., Lynam D., Staton M., Brogli B., Flory K., and Clayton R.R. The association of testosterone with nicotine use in young adult females. Addict Behaviour 26 (2001) 279-283
180. Martín-Calderón J.L., Muñoz R.M., Villanua M.A., del Arco I., Moreno J.L., de Fonseca F.R., and Navarro M. Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. European Journal of Pharmacology 344 (1998) 77-86
181. Matta S.G., Beyer H.S., McAllen K.M., and Sharp B.M. Nicotine elevates rat plasma ACTH by a central mechanism. Journal of Pharmacology and Experimental Therapeutics 243 (1987) 217-226
182. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., and Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 50 (1995) 83-90
183. Moffatt R.J., and Owens S.G. Cessation from cigarette smoking: changes in body weight, body composition, resting metabolism, and energy consumption. Metabolism 40 (1991) 465-470
184. Mortality Morbidity Weekly Report. Youth Tobacco Surveillance-United States, 1998-1999. MMW 49 SS10 (2000) 1-93
185. Mortality Morbidity Weekly Report. Cigarette Smoking Among Adults-United States, 2000. MMW 51 29 (2002) 642-645
186. Nashmi R., Dickinson M.E., McKinney S., Jareb M., Labarca C., Fraser S.E., and Lester H.A. Assembly of alpha4beta2 nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: effects of localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons. Journal of Neuroscience 23 (2003) 11554-11567
187. Nelson D.E., Giovino G.A., Shopland D.R., Mowery P.D., Mills S.L., and Eriksen M.P. Trends in cigarette smoking among US adolescents, 1974 through 1991. American Journal of Public Health 85 (1995) 34-40
188. Nelson M.E., Kuryatov A., Choi C.H., Zhou Y., and Lindstrom J. Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors. Molecular Pharmacology 63 (2003) 332-341
189. Netter P., Hennig J., Huwe S., and Olbrich R. Personality related effects of nicotine, mode of application, and expectancies on performance, emotional states, and desire for smoking. Psychopharmacology 135 (1998) 52-62
190. Ogden J. Effects of smoking cessation, restrained eating, and motivational states on food intake in the laboratory. Health Psychology 13 (1994) 114-121
191. Ohno-Shosaku T., Maejima T., and Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29 (2001) 729-738
192. Okada S., Shimizu T., and Yokotani K. Extrahypothalamic corticotropin-releasing hormone mediates (-)-nicotine-induced elevation of plasma corticosterone in rats. European Journal of Pharmacology 473 (2003) 217-223
193. Okuda H., Shioda S., Nakai Y., Nakayama H., Okamoto M., and Nakashima T. The presence of corticotropin-releasing factor-like immunoreactive synaptic vesicles in axon terminals with nicotinic acetylcholine receptor-like immunoreactivity in the median eminence of the rat. Neuroscience Letters 161 (1993) 183-186
194. Onaivi E.S., Green M.R., and Martin B.R. Pharmacological characterization of cannabinoids in the elevated plus maze. Journal of Pharmacology and Experimental Therapeutics 253 (1990) 1002-1009
195. Ouagazzal A.M., Kenny P.J., and File S.E. Modulation of behaviour on trials 1 and 2 in the elevated plus-maze test of anxiety after systemic and hippocampal administration of nicotine. Psychopharmacology 144 (1999) 54-60
196. Ouagazzal A.M., Kenny P.J., and File S.E. Stimulation of nicotinic receptors in the lateral septal nucleus increases anxiety. European Journal of Neuroscience 11 (1999) 3957-3962
197. Oz M., Zhang L., Ravindran A., Morales M., and Lupica C.R. Differential effects of endogenous and synthetic cannabinoids on alpha7-nicotinic acetylcholine receptor-mediated responses in Xenopus Oocytes. Journal of Pharmacology and Experimental Therapeutics 310 (2004) 1152-1160
198. Parrott A.C. Acute pharmacodynamic tolerance to the subjective effects of cigarette smoking. Psychopharmacology 116 (1994) 93-97
199. Parrott A.C. Stress modulation over the day in cigarette smokers. Addiction 90 (1995) 233-244
200. Parrott A.C. Does cigarette smoking cause stress?. American Psychology 54 (1999) 817-820
201. Patton G.C., Coffey C., Carlin J.B., Degenhardt L., Lynskey M., and Hall W. Cannabis use and mental health in young people: cohort study. British Medical Journal 325 (2002) 1195-1198
202. Patton G.C., Coffey C., Carlin J.B., Sawyer S.M., and Lynskey M. Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction 100 (2005) 1518-1525
203. Pauly J.R., Marks M.J., Gross S.D., and Collins A.C. An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment. Journal of Pharmacology and Experimental Therapeutics 258 (1991) 1127-1136
204. Penetar D.M., Kouri E.M., Gross M.M., McCarthy E.M., Rhee C.K., Peters E.N., and Lukas S.E. Transdermal nicotine alters some of marihuana's effects in male and female volunteers. Drug and Alcohol Dependence 79 (2005) 211-223
205. Perkins K.A., Epstein L.H., Marks B.L., Stiller R.L., and Jacob R.G. The effect of nicotine on energy expenditure during light physical activity. New England Journal of Medicine 320 (1989) 898-903
206. Perkins K.A., Epstein L.H., Sexton J.E., Solberg-Kassel R., Stiller R.L., and Jacob R.G. Effects of nicotine on hunger and eating in male and female smokers. Psychopharmacology 106 (1992) 53-59
207. Perkins K.A., Sexton J.E., Stiller R.L., Fonte C., DiMarco A., Goettler J., and Scierka A. Subjective and cardiovascular responses to nicotine combined with caffeine during rest and casual activity. Psychopharmacology 113 (1994) 438-444
208. Perkins K.A., Donny E., and Caggiula A.R. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine and Tobacoo Research 1 (1999) 301-315
209. Perry D.C., Davila-Garcia M.I., Stockmeier C.A., and Kellar K.J. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. Journal of Pharmacology and Experimental Therapeutics 289 (1999) 1545-1552
210. Phillips S., and Fox P. An investigation into the effects of nicotine gum on short-term memory. Psychopharmacology 140 (1998) 429-433
211. Picciotto M.R. Nicotine as a modulator of behavior: beyond the inverted U. Trends in Pharmacological Science 24 (2003) 493-499
212. Picciotto M.R., and Zoli M. Nicotinic receptors in aging and dementia. Journal of Neurobiology 53 (2002) 641-655
213. Picciotto M.R., Caldarone B.J., King S.L., and Zachariou V. Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 22 (2000) 451-465
214. Picciotto M.R., Brunzell D.H., and Caldarone B.J. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 13 (2002) 1097-1106
215. Pierce J.P., and Gilpin E. How long will today's new adolescent smoker be addicted to cigarettes?. American Journal of Public Health 86 (1996) 253-256
216. Piomelli D. The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience 4 (2003) 873-884
217. Pomerleau O.F. Endogenous opioids and smoking: a review of progress and problems. Psychoneuroendocrinology 23 (1998) 115-130
218. Pomerleau C.S., Ehrlich E., Tate J.C., Marks J.L., Flessland K.A., and Pomerleau O.F. The female weight-control smoker: a profile. Journal of Substance Abuse 5 (1993) 391-400
219. Porath A.J., and Fried P.A. Effects of prenatal cigarette and marijuana exposure on drug use among offspring. Neurotoxicological Teratology 27 (2005) 267-277
220. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., Nomikos G.G., Carter P., Bymaster F.P., Leese A.B., and Felder C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. Journal of Pharmacology and Experimental Therapeutics 301 (2002) 1020-1024
221. Presburger G., and Robinson J.K. Spatial signal detection in rats is differentially disrupted by delta-9-tetrahydrocannabinol, scopolamine, and MK-801. Behavioural Brain Research 99 (1999) 27-34
222. Pryor G.T., Larsen F.F., Husain S., and Braude M.C. Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats. Pharmacology Biochemistry and Behaviour 8 (1978) 295-318
223. Pugh Jr. G., Mason Jr. D.J., Combs V., and Welch S.P. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP 55,940 in the spinal cord. Journal of Pharmacology and Experimental Therapeutics 281 (1997) 730-737
224. Quattrocki E., Baird A., and Yurgelun-Todd D. Biological aspects of the link between smoking and depression. Harvard Review of Psychiatry 8 (2000) 99-110
225. Ravinet-Trillou C., Delgorge C., Menet C., Arnone M., and Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. International Journal of Obesity and Related Metabolic Disorders 28 (2004) 640-648
226. Rigotti N.A., Lee J.E., and Wechsler H. US college students' use of tobacco products: results of a national survey. Journal of the American Medical Association 284 (2000) 699-705
227. Rodríguez de Fonseca F., Rubio P., Menzaghi F., Merlo-Pich E., Rivier J., Koob G.F., and Navarro M. Corticotropin-releasing factor (CRF) antagonist [D-Phe12, Nle21,38, CaMeLeu37] CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. Journal of Pharmacology and Experimental Therapeutics 276 (1996) 56-64
228. Romero E.M., Fernández B., Sagredo O., Gómez N., Urigüen L., Guaza C., De Miguel R., Ramos J.A., and Viveros M.P. Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. Developmental Brain Research 136 (2002) 85-92
229. Ross S.A., Wong J.Y., Clifford J.J., Kinsella A., Massalas J.S., Horne M.K., Scheffer I.E., Kola I., Waddington J.L., Berkovic S.F., and Drago J. Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. Journal of Neuroscience 20 (2000) 6431-6441
230. Rowan G.A., and Flaherty C.F. The effects of morphine in the consummatory contrast paradigm. Psychopharmacology 93 (1987) 51-58
231. Schatz A.R., Lee M., Condie R.B., Pulaski J.T., and Kaminski N.E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicology and Applied Pharmacology 142 (1997) 278-287
232. Schochet T.L., Kelley A.E., and Landry C.F. Differential behavioral effects of nicotine exposure in adolescent and adult rats. Psychopharmacology 175 (2004) 265-273
233. Seguire M., and Chalmers K.I. Late adolescent female smoking. Journal of Advanced Nursing 31 (2000) 1422-1429
234. Shoaib M., and Bizarro L. Deficits in a sustained attention task following nicotine withdrawal in rats. Psychopharmacology 178 (2005) 211-222
235. Slotkin T.A. Nicotine and the adolescent brain: insights from an animal model. Neurotoxicological Teratology 24 (2002) 369-384
236. Solowij N., Stephens R.S., Roffman R.A., Babor T., Kadden R., Miller M., Christiansen K., McRee B., and Vendetti J. Marijuana Treatment Project Research Group. Cognitive functioning of long-term heavy cannabis users seeking treatment. Journal of the American Medical Association 287 (2002) 1123-1131
237. Sonntag H., Wittchen H.U., Hofler M., Kessler R.C., and Stein M.B. Are social fears and DSM-IV social anxiety disorder associated with smoking and nicotine dependence in adolescents and young adults?. European Psychiatry 15 (2000) 67-74
238. Sparks J.A., and Pauly J.R. Effects of continuous oral nicotine administration on brain nicotinic receptors and responsiveness to nicotine in C57Bl/6 mice. Psychopharmacology 141 (1999) 145-153
239. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neuroscience and Biobehavioural Reviews 24 (2000) 417-463
240. Spielberger C.D., and Jacobs G.A. Personality and smoking behavior. Journal of Personality Assessment 46 (1982) 396-403
241. Spilich G.J., June L., and Renner J. Cigarette smoking and cognitive performance. British Journal of Addiction 87 (1992) 1313-1326
242. Spring B., Pagoto S., McChargue D., Hedeker D., and Werth J. Altered reward value of carbohydrate snacks for female smokers withdrawn from nicotine. Pharmacology Biochemistry and Behaviour 76 (2003) 351-360
243. Stamford B.A., Matter S., Fell R.D., and Papanek P. Effects of smoking cessation on weight gain, metabolic rate, caloric consumption, and blood lipids. American Journal of Clinical Nutrition 43 (1986) 486-494
244. Stanton W.R., McClelland M., Elwood C., Ferry D., and Silva P.A. Prevalence, reliability and bias of adolescents' reports of smoking and quitting. Addiction 91 (1996) 1705-1714
245. Stolerman I.P. Behavioural pharmacology of nicotine: multiple mechanisms. British Journal of Addiction 86 (1991) 533-536
246. Stolerman I.P., Mirza N.R., Hahn B., and Shoaib M. Nicotine in an animal model of attention. European Journal of Pharmacology 393 (2000) 147-154
247. Substance Abuse and Mental Health Services Administration. Results from the 2003 National Survey on Drug Use and Health: National Findings (2004), Substance Abuse and Mental Health Services Administration, Rockville
248. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., and Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochemistry and Biophysics Research Communications 215 (1995) 89-97
249. Sullivan J.M. Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids. Learning and Memory 7 (2000) 132-139
250. Sundram S. Cannabis and neurodevelopment: implications for psychiatric disorders. Human Psychopharmacology 21 (2006) 245-254
251. Swan G.E., Denk C.E., Parker S.D., Carmelli D., Furze C.T., and Rosenman R.H. Risk factors for late relapse in male and female ex-smokers. Addictive Behaviour 13 (1988) 253-266
252. Sztalryd C., Hamilton J., Horwitz B.A., Johnson P., and Kraemer F.B. Alterations of lipolysis and lipoprotein lipase in chronically nicotine-treated rats. American Journal of Physiology 270 (1996) E215-E223
253. Szyndler J., Sienkiewicz-Jarosz H., Maciejak P., Siemiatkowski M., Rokicki D., Czlonkowska A.I., and Plaznik A. The anxiolytic-like effect of nicotine undergoes rapid tolerance in a model of contextual fear conditioning in rats. Pharmacology Biochemistry and Behaviour 69 (2001) 511-518
254. Tobacco Advisory Group, Royal College of Physicians. Nicotine Addiction in Britain (2000), RCP, London
255. Tournier M., Sorbara F., Gindre C., Swendsen J.D., and Verdoux H. Cannabis use and anxiety in daily life: a naturalistic investigation in a non-clinical population. Psychiatry Research 118 (2003) 1-8
256. Trauth J.A., Seidler F.J., and Slotkin T.A. Persistent and delayed behavioral changes after nicotine treatment in adolescent rats. Brain Research 880 (2000) 167-172
257. Tsou K., Brown S., Sañudo-Peña M.C., Mackie K., and Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1998) 393-411
258. Tucci S., Cheeta S., Genn R.F., Seth P., and File S.E. Anxiety conditioned to nicotine in the elevated plus-maze is time dependent. Behavioural Pharmacology 13 (2002) 615-620
259. Tucci S., Cheeta S., Seth P., and File S.E. Corticotropin releasing factor antagonist, alpha-helical CRF (9-41), reverses nicotine-induced conditioned, but not unconditioned, anxiety. Psychopharmacology 167 (2003) 251-256
260. Tucci S., Genn R.F., Marco E., and File S.E. Do different mechanisms underlie two anxiogenic effects of systemic nicotine?. Behavioural Pharmacology 14 (2003) 323-329
261. Tucci S.A., Genn R.F., and File S.E. Methyllycaconitine (MLA) blocks the nicotine evoked anxiogenic effect and 5-HT release in the dorsal hippocampus: possible role of alpha7 receptors. Neuropharmacology 44 (2003) 367-373
262. Tullis L.M., Dupont R., Frost-Pineda K., and Gold M.S. Marijuana and tobacco: a major connection?. Journal of Addictive Diseases 22 (2003) 51-62
263. Valjent E., Mitchell J.M., Besson M.J., Caboche J., and Maldonado R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. British Journal of Pharmacology 135 (2002) 564-578
264. 9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. European Journal of Neuroscience 13 (2001) 1816-1824
265. Van der Stelt M., and Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. European Journal of Pharmacology 480 (2003) 133-150
266. Verrico C.D., Jentsch J.D., Roth R.H., and Taylor J.R. Repeated, intermittent delta(9)-tetrahydrocannabinol administration to rats impairs acquisition and performance of a test of visuospatial divided attention. Neuropsychopharmacology 29 (2004) 522-529
267. Vickers S.P., and Kennett G.A. Cannabinoids and the regulation of ingestive behaviour. Current Drug Targets 6 (2005) 215-223
268. Viveros M.P., and Marco E.M. Cannabinoids, anxiety and depression. In: Govil J.N., and Singh V.K. (Eds). Recent Progress in Medicinal Plants, vol. 18, Chronic and Comman Diseases-II (2006), Stadium Press, LLC, USA
269. Viveros M.P., Llorente R., Moreno E., and Marco E.M. Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods. Behavioural Pharmacology 16 (2005) 353-362
270. Viveros M.P., Marco E.M., and File S.E. Endocannabinoid system and stress and anxiety responses. Pharmacology Biochemistry and Behaviour 81 (2005) 331-342
271. Wada E., Wada K., Boulter J., Deneris E., Heinemann S., Patrick J., and Swanson L.W. Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. Journal of Comparative Neurology 284 (1989) 314-335
272. Waldbillig R.J., Bartness T.J., and Stanley B.G. Increased food intake, body weight, and adiposity in rats after regional neurochemical depletion of serotonin. Journal of Comparative and Physiological Psychology 95 (1981) 391-405
273. Warburton D.M., and Mancuso G. Evaluation of the information processing and mood effects of a transdermal nicotine patch. Psychopharmacology 135 (1998) 305-310
274. Weidenfeld J., Feldman S., and Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 59 (1994) 110-112
275. Wenger T., Jamali K.A., Juaneda C., Leonardelli J., and Tramu G. Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochemistry and Biophysics Research Communications 237 (1997) 724-728
276. West R., and Hajek P. What happens to anxiety levels on giving up smoking?. American Journal of Psychiatry 154 (1997) 1589-1592
277. Whiteaker P., Davies A.R., Marks M.J., Blagbrough I.S., Potter B.V., Wolstenholme A.J., Collins A.C., and Wonnacott S. An autoradiographic study of the distribution of binding sites for the novel alpha7-selective nicotinic radioligand [3H]-methyllycaconitine in the mouse brain. European Journal of Neuroscience 11 (1999) 2689-2696
278. Whiteaker P., Jimenez M., McIntosh J.M., Collins A.C., and Marks M.J. Identification of a novel nicotinic binding site in mouse brain using [(125)I]-epibatidine. British Journal of Pharmacology 131 (2000) 729-739
279. Whiteaker P., Marks M.J., Grady S.R., Lu Y., Picciotto M.R., Changeux J.P., and Collins A.C. Pharmacological and null mutation approaches reveal nicotinic receptor diversity. European Journal of Pharmacology 393 (2000) 123-135
280. Whiteaker P., Peterson C.G., Xu W., McIntosh J.M., Paylor R., Beaudet A.L., Collins A.C., and Marks M.J. Involvement of the alpha3 subunit in central nicotinic binding populations. Journal of Neuroscience 22 (2002) 2522-2529
281. Wilson R.I., and Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410 (2001) 588-592 (Erratum in Nature 411, 974)
282. Wonnacott S. Nicotinic involvement in ACh-DA interaction?. Trends in Pharmacological Sciences 10 (1989) 395-396
283. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends in Neuroscience 20 (1997) 92-98
284. Xu Z., Seidler F.J., Ali S.F., Slikker Jr. W., and Slotkin T.A. Fetal and adolescent nicotine administration: effects on CNS serotonergic systems. Brain Research 914 (2001) 166-178
285. Xu Z., Seidler F.J., Cousins M.M., Slikker Jr. W., and Slotkin T.A. Adolescent nicotine administration alters serotonin receptors and cell signaling mediated through adenylyl cyclase. Brain Research 951 (2002) 280-292
286. Young J.W., Finlayson K., Spratt C., Marston H.M., Crawford N., Kelly J.S., and Sharkey J. Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Neuropsychopharmacology 29 (2004) 891-900
287. Zimmer A., Valjent E., König M., Zimmer A.M., Robledo P., Hahn H., Valverde O., and Maldonado R. Absence of Δ-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. Journal of Neuroscience 21 (2001) 9499-9505
288. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., and Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA 96 (1999) 5780-5785
289. Zvolensky M.J., Feldner M.T., Leen-Feldner E.W., Gibson L.E., Abrams K., and Gregor K. Acute nicotine withdrawal symptoms and anxious responding to bodily sensations: a test of incremental predictive validity among young adult regular smokers. Behaviour Research and Therapy 43 (2005) 1683-1700